Clin2
NCT07381257Possibly a fitRecruiting

Rifaximin for fatty liver disease

Metabolic Dysfunction-Associated Steatotic Liver Disease

Treatments studied

Part of Digestive system, Hormones & metabolism clinical trials.

This trial tests if rifaximin, a gut medication, can help reduce liver fat in people with metabolic fatty liver disease. It may be an option if you have at least one metabolic risk factor and a certain amount of liver fat.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
60 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Be between 18 and 75 years old
  • Have been diagnosed with fatty liver in the last 6 months
  • Have at least one metabolic risk factor (e.g., high BMI, high blood sugar, high triglycerides, low 'good' cholesterol, or high blood pressure)
  • Your liver fat must be at least 8% on a special MRI scan
  • Not have cirrhosis or other serious liver diseases
  • Not have used certain antibiotics or gut medications in the last 4 weeks

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06873165Recruiting
Gut bacteria treatment for fatty liver disease

This study tests whether a specially designed gut bacteria treatment can help people with fatty liver disease and related health issues like high blood sugar, high cholesterol, or high blood pressure. It aims to see if the treatment is safe and improves liver health.

Taipei
NCT07165028Recruiting· Phase 3
Study of new drugs for fatty liver with scarring

This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.

Tuscaloosa, Alabama
NCT06703450Enrolling by invitation
Liver fibrosis study with MRI for MASLD patients

This study is testing whether an MRI can help doctors see liver scarring (fibrosis) in people with MASLD, a type of fatty liver disease. It is for patients who already need a liver biopsy as part of their care, to compare the MRI results with the biopsy.

New York, New York
NCT06704516Recruiting· Phase 1
HRT and fatty liver disease in menopausal women – a pilot study

This study tests whether starting hormone replacement therapy (HRT) improves liver health in women with menopause and fatty liver disease (MASLD). It aims to understand how HRT might help reduce fat in the liver.

Oxford, Oxfordshire
NCT07185932Recruiting· Early Phase 1
Rifaximin for fatty liver with metabolic issues

This trial tests if rifaximin, a gut-targeted antibiotic, can help people with fatty liver disease who also have metabolic problems like obesity or diabetes. You need a recent fatty liver diagnosis and a liver fat level of at least 8% on an MRI scan.

Shanghai, Shanghai Municipality
NCT06891365Recruiting· Phase 1
Multiple doses of a new drug for fatty liver disease

This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.

Harrow

Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.